Alivus Life Sciences Board of Directors

Get the latest insights into the leadership at Alivus Life Sciences. Learn about the experienced professionals guiding the company's strategy and governance.

NamePosition
Mr. Hiren K Patel Chairman & Non-Exe.Director
Dr. Yasir Rawjee Managing Director & CEO
Mr. Vinod Naik Executive Director
Mr. Kaushikbhai N Patel Independent Director
Dr. Savan Godiawala Independent Director
Mr. Taruvai Laxminarayanan Easwar Independent Director
Mrs. Manju Agarwal Independent Director

Alivus Life Sciences Share price

ALIVUS

941.7

6.80 (-0.72%)
NSE
BSE
Last updated on 28 Aug, 2025 | 15:31 IST
BUYSELL
Today's High

956.00

Today's Low

935.20

52 Week Low

850.00

52 Week High

1335.10

The current prices are delayed, login to your account for live prices

Alivus Life Sciences FAQs

The board at Alivus Life Sciences consists of experienced professionals, including Mr. Hiren K Patel , Dr. Yasir Rawjee , and others, overseeing the company’s strategic and corporate governance.

Directors at Alivus Life Sciences are typically nominated by the Nomination and Remuneration Committee and approved by shareholders, adhering to regulatory and governance standards. While this is the standard procedure, the exact process may differ depending on the company’s internal policies and governance framework.

As of the latest update, Mr. Hiren K Patel is the current chairman at Alivus Life Sciences.

Executive directors at Alivus Life Sciences are involved in day-to-day operations, while non-executive directors, including independents, provide oversight and strategic input. While this distinction is generally followed, the specific responsibilities of executive and non-executive directors may vary based on the company’s organisational structure and governance practices.

Yes, Alivus Life Sciences adheres to all applicable SEBI and Companies Act provisions related to board structure, diversity, and independence.

At Alivus Life Sciences, board members usually serve fixed terms as outlined in the company’s charter or governance policy, commonly ranging between three to five years, with the possibility of renewal based on performance, shareholder approval, and regulatory norms.